Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors.

Jonuleit, T; Peschel, C; Schwab, R; van der Kuip, H; Buchdunger, E; Fischer, T; Huber, C; Aulitzky, W E

Jonuleit, T; Peschel, C; Schwab, R; van der Kuip, H; Buchdunger, E; Fischer, T; Huber, C; Aulitzky, W E.

Affiliation

Jonuleit T; Department of Haematology, Robert Bosch Hospital, Stuttgart, Germany.

Br J Haematol ; 100(2): 295-303, 1998 Feb.

Article in En | MEDLINE | ID: mdl-9488616

Subject(s)

Cell Cycle/drug effects; Fusion Proteins, bcr-abl/pharmacology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology; Protein-Tyrosine Kinases/pharmacology; Benzamides; Cell Division; Enzyme Inhibitors/pharmacology; Growth Substances/metabolism; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Piperazines/pharmacology; Protein-Tyrosine Kinases/antagonists & inhibitors; Pyrimidines/pharmacology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Cell Cycle / Fusion Proteins, bcr-abl Limits: Humans Language: En Journal: Br J Haematol Year: 1998 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links